Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
(American Society for Radiation Oncology) Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the January 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics, the official scientific journal of the American Society for Radiation Oncology.
Approximately 50% of all cancer patients undergo radiation therapy (RT) as part of their primary treatment regimen. During RT, high dosages of ionizing radiation are delivered which generate oxygen-derived free radicals. These radicals induce DNA damage and eventually cause apoptosis.[2,3] The addition of RT to a treatment regimen is generally associated with a reduction in recurrences and improvement of prognosis in many types of cancer.[4 –8] However, RT is also known to cause acute and late toxicity.
CONCLUSIONS: The results of our study show that HDR-IORT could be a valuable asset in the multimodality management of LARC, LRRC and RS. PMID: 29745309 [PubMed - as supplied by publisher]
We aimed to investigate the patterns of care and overall survival (OS) for metastatic rectal cancer patients treated with chemotherapy, radiation therapy (RT), or with a multimodality approach, utilizing a large national registry of patients.
We present a practical overview regarding the state of the art of the MRI protocol, the main signs that radiologists should consider for their reports during their clinical activity and future perspectives.Teaching Points•MRI protocol for rectal cancer staging and re-staging.•MRI findings that radiologists should consider for reports during everyday clinical activity.•Perspectives regarding the development of latest technologies.
AbstractPurpose of ReviewColorectal cancer has a high global incidence, and standard treatment employs a multimodality approach. In addition to cure, minimizing treatment-related toxicity and improving the therapeutic ratio is a common goal. The following article addresses the potential of omitting radiotherapy in select rectal cancer patients.Recent FindingsOmission of radiotherapy in rectal cancer is analyzed in the context of historical findings, as well as more recent data describing risk stratification of stage II –III disease, surgical optimization, imaging limitations, improvement in systemic chemotherapeutic ...
Conclusion: CB-IMRT satisfies the requirements of clinical therapy and can be used in a radiotherapy routine.
Conclusions: In this cohort of patients, sociodemographic factors such as race/ethnicity, insurance status, and socioeconomic status, did not influence the receipt of radiation. Further research is needed, however, to understand why aging, greater comorbidity, and having surgery present a barrier to radiation therapy, particularly given that it is a well-tolerated treatment in most patients.
Rectal cancer predominantly affects patients older than 70 years, with peak incidence at age 80 to 85 years. However, the standard treatment paradigm for rectal cancer oftentimes cannot be feasibly applied to these patients owing to frailty or comorbid conditions. There are currently little information and no treatment guidelines to help direct therapy f or patients who are elderly and/or have significant comorbidities, because most are not included or specifically studied in clinical trials. More recently various alternative treatment options have been brought to light that may potentially be utilized in this group of patients.
This study aims to assess outcomes and identify prognostic factors for patients with LRRC treated using a multimodality treatment protocol.MethodsAn analysis of a prospectively maintained institutional database of consecutive patients who underwent radical surgical resection for LRRC was performed. Potential prognostic factors were investigated using a Cox proportional hazards model.ResultsNinety-eight patients were included in this study. A multimodality approach was taken in the majority, including preoperative chemoradiation (78%), intraoperative radiation therapy (47%) and adjuvant chemotherapy (41%). Extended resectio...
The concept of organ preservation in rectal cancer is now less controversial than it used to be (1, 2). The benefits from avoiding radical proctectomy and its associated immediate morbidity and mortality, functional consequences, and requirement for stomas have been demonstrated in multiple series (3, 4). Coupled with the acceptable oncologic outcomes following no immediate surgery, patients with complete clinical response (including clinical, endoscopic, and radiological) are now offered or at least are made aware of this “Watch&Wait ” strategy (5, 6).